ARCHIVES

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Researcher Falsified EMF Data, ORI Says

July 30, 1999

HCFA Chief Says Facts Will Not Matter, She Won’t Loosen DRGs For Clinical Trials Unless Congress Orders It

May 4, 1984

IARC Director Denies NCI Staff Interference With Monograph

May 28, 1982

Insurer Declines To Cover Avastin For Breast Cancer, Institutes Review Procedure For Exceptional Cases

October 21, 2011

Draft Report Outlines New Toxicological Test Criteria

November 24, 1995

FPD-R Regimen Well-Tolerated, With 63 Percent Complete Response

July 29, 2011